Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.86 -0.5%	$1.78	$1.21 ▼ $3.81	$45.94M	0.68	252,870 shs	43,111 shs
CRDF Cardiff Oncology	$3.59 +2.3%	$3.15	$2.01 ▼ $5.64	$233.51M	1.52	1.20 million shs	1.41 million shs
IMAB I-Mab	$2.29 -2.1%	$1.59	$0.60 ▼ $3.08	$191.09M	1.4	390,149 shs	485,354 shs
MDWD MediWound	$19.12 -0.4%	$19.70	$14.14 ▼ $24.00	$207.51M	0.32	86,510 shs	40,344 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-0.53%	-1.59%	+10.06%	+9.41%	+40.91%
CRDF Cardiff Oncology	+2.28%	+15.81%	+7.16%	+25.09%	+72.60%
IMAB I-Mab	-2.14%	-17.63%	+78.91%	+213.66%	+44.94%
MDWD MediWound	-0.42%	-2.05%	-14.03%	+19.50%	+22.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.5946 of 5 stars	1.0	0.0	1.1	2.5	1.3
CRDF Cardiff Oncology	1.6866 of 5 stars	3.4	1.0	2.7	0.0	0.6
IMAB I-Mab	3.0741 of 5 stars	3.7	3.0	2.9	1.7	0.6
MDWD MediWound	1.8184 of 5 stars	3.5	1.0	2.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	-10.39% Downside
CRDF Cardiff Oncology	2.80	Moderate Buy	$9.88	175.07% Upside
IMAB I-Mab	3.33	Buy	$6.00	162.01% Upside
MDWD MediWound	3.00	Buy	$31.80	66.32% Upside

Current Analyst Ratings Breakdown

Latest AADI, MDWD, CRDF, and IMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/4/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/4/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.83	N/A	N/A	$4.29 per share	0.43
CRDF Cardiff Oncology	$680K	351.24	N/A	N/A	$1.86 per share	1.93
IMAB I-Mab	$3.89M	48.07	N/A	N/A	$2.47 per share	0.93
MDWD MediWound	$20.22M	10.22	N/A	N/A	$2.89 per share	6.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	8/5/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)

Latest AADI, MDWD, CRDF, and IMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
CRDF Cardiff Oncology	N/A	6.22	6.22
IMAB I-Mab	N/A	22.35	22.35
MDWD MediWound	N/A	2.15	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
CRDF Cardiff Oncology	16.29%
IMAB I-Mab	38.38%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
CRDF Cardiff Oncology	7.70%
IMAB I-Mab	22.10%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable

AADI, MDWD, CRDF, and IMAB Headlines

Recent News About These Companies

MediWound Ltd. (NASDAQ:MDWD) Receives Consensus Rating of "Buy" from Analysts

July 2 at 3:31 AM | americanbankingnews.com

MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Buy" by Analysts

June 27, 2025 | marketbeat.com

MediWound Ltd. (MDWD) latest stock news and headlines - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

MediWound (NASDAQ:MDWD) Shares Pass Above Fifty Day Moving Average - Time to Sell?

June 25, 2025 | marketbeat.com

MediWound Ltd. (NASDAQ:MDWD) Shares Acquired by Silverberg Bernstein Capital Management LLC

June 3, 2025 | marketbeat.com

Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth

June 2, 2025 | finance.yahoo.com

MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges

May 21, 2025 | tipranks.com

MediWound (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

May 21, 2025 | zacks.com

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025 | globenewswire.com

MediWound Q1 2025 Earnings Preview

May 20, 2025 | msn.com

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025 | seekingalpha.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025 | globenewswire.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

April 17, 2025 | finance.yahoo.com

MediWound reports Q4 EPS (36c), consensus (61c)

March 20, 2025 | markets.businessinsider.com

MediWound files $125M mixed securities shelf

March 20, 2025 | markets.businessinsider.com

Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

March 20, 2025 | finance.yahoo.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

March 20, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI, MDWD, CRDF, and IMAB Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.86 -0.01 (-0.53%)

As of 07/1/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Cardiff Oncology NASDAQ:CRDF

$3.59 +0.08 (+2.28%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$3.58 0.00 (-0.14%)

As of 07/2/2025 07:56 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

I-Mab NASDAQ:IMAB

$2.29 -0.05 (-2.14%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$2.34 +0.04 (+1.97%)

As of 07/2/2025 07:56 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

MediWound NASDAQ:MDWD

$19.12 -0.08 (-0.42%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$19.14 +0.02 (+0.10%)

As of 07/2/2025 04:30 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time